Behavior Core

行为核心(BC)建立在评估促进疼痛的行为方面的专业知识的坚实基础上 现场和早期药物发现和开发。行为核心主任爱德华·比尔斯基博士是一位- 久负盛名的行为药理学家，一直致力于开发治疗糖尿病的新型止痛药 急性和慢性疼痛。除了他的研究获得了大量的资助外，比尔斯基博士还与 生物技术和制药公司，并共同创立了两家公司，其中一家已经成功 将一种候选药物带入临床试验。不列颠哥伦比亚省经验丰富的员工为 与疼痛相关的广泛行为菜单和潜在的止痛药副作用。《BC》规定：(A) 实验室之间的标准化方案和培训，以减少变异性并增加重复性和 伤害性行为测量的有效性；(B)高级培训和模型开发和验证 (例如，情感、认知和疼痛抑制等反射性伤害性反应的替代方案 (C)为许多行为分析和外科手术提供一个集中的空间。在第一阶段， BC团队成功地支持和培训了Cobre人员，持续接待优秀用户 对其提供的服务进行评论。这些服务将继续提供给Cobre项目负责人 和其他调查人员在第二阶段。此外，BC将增加其服务，以满足日益增长的需求 科布雷的调查员。新的发展包括扩大育种和基因分型服务，以支持 提高转基因小鼠模型的利用率，并支持研究人员利用 行为研究中的光遗传学方法。将为核心研究人员提供持续培训 确保能够为Cobre调查人员提供最高水平的创新和支持。在扩张中 核心服务，不列颠哥伦比亚省主任与邻近的Cobre和INBRE密切合作 缅因州医学研究所和芒特荒岛生物实验室的研究中心。 与其他区域资源的这种协调将使BC能够在其准备 长期可持续性。可持续发展还将通过实施按服务收费模式和通过 继续与行业合作伙伴合作。行为核心对于研究的成功是不可或缺的 科布雷调查人员的努力。对其能力的持续投资将使Core能够提供 动物研究的最新实验工具，并帮助核心向财政独立过渡。穿过 利用这些服务，研究人员和受训人员能够测试用于治疗癌症的新化合物 疼痛，同时获得对神经系统功能和急性和慢性疾病机制的关键见解 疼痛。

The Behavior Core (BC) is built on a strong foundation of expertise in assessing behaviors to advance the pain field and early-stage drug discovery and development. Behavior Core Director Dr. Edward Bilsky is a well- established behavioral pharmacologist who has focused on developing novel analgesics for the treatment of acute and chronic pain. In addition to receiving numerous grants for his research, Dr. Bilsky has worked with biotechnology and pharmaceutical companies, and co-founded two companies, one of which has successfully brought a drug candidate into clinical trials. The BC’s experienced staff provides training and support for an extensive menu of behaviors related to pain and potential analgesic drug side-effects. The BC provides (a) standardized protocols and training between laboratories to reduce variability and increase reproducibility and validity for measures of nociceptive behavior; (b) advanced training and model development and validation (e.g., alternatives to reflexive nociceptive responses such as affective, cognitive and pain-suppressed readouts); (c) a centralized space for many behavioral assays and surgical procedures. During Phase I, the BC team successfully supported and trained COBRE personnel, consistently receiving outstanding user reviews on the services it provides. These services will continue to be provided to COBRE Project Leaders and other investigators during Phase II. In addition the BC will increase its offerings to meet the growing needs of COBRE investigators. New developments include expanded breeding and genotyping services to support the increased utilization of genetically modified mouse models, and support for investigators’ utilization of optogenetic approaches in behavioral studies. Continued training of Core research staff will be provided to ensure that the highest level of innovation and support can be provided to COBRE investigators. In expanding the Core services, the BC Director has worked closely with neighboring COBRE and INBRE supported research cores at the Maine Medical Research Institute and the Mount Desert Island Biological Laboratory. This coordination with other regional resources will allow the BC to broaden its user base as it prepares for long-term sustainability. Sustainability will also be facilitated by implementing a fee-for-service model and by continuing to work with industry partners. The Behavior Core is indispensible to the success of the research efforts of COBRE investigators. Continued investments in its capabilities will allow the Core to provide the latest experimental tools in animal research and help the Core transition to fiscal independence. Through utilization of these services, researchers and trainees are able to test novel compounds for the treatment of pain while gaining key insights into the function of the nervous system and mechanisms of acute and chronic pain.